ProfessorJohn Simes

A framework for extrapolating evidence for targeted therapies in rare biomarker-defined cancers

Augmenting biocuration with systematic evidence synthesis to support therapeutic decision making in precision oncology

Bridging the efficacy-effectiveness gap in lung cancer: Using real-world data to inform future research, healthcare policy and clinical practice

Cancer and cardiovascular disease – evaluating shared disease pathways to inform future trial designs for improvement of patient outcomes.

Cancer clinical trial design in the era of targeted and immunological therapies

Changes to design aspects of ongoing randomised controlled trials

Improving methods for generalisability of precision oncology research.

Improving the evaluation and reporting of adverse events in clinical trials of systemic therapy in patients with advanced cancers

Next generation systematic review methodology

Optimising clinical trial designs in the era of precision oncology

Optimising the translation of research into practice and policy through the adoption of living evidence methods

Precision oncology in gynaecological cancers

Validation of surrogate endpoints used in clinical trials of immune checkpoint inhibitors and targeted therapies in advanced cancers